CD19 and diffuse large B-cell lymphoma: Phase III studies comparing anti‐CD19 CAR T‐cell therapy and the current standard of care with salvage therapy followed by HDC‐ASCT as second‐line therapy for rel/ref DLBCL (NCT03570892, NCT03575351, and NCT03391466) are currently being conducted.